Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.49 |
| ▸ | CNR1 | P21554 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115369 | 0.75 | ADORA1 (0.50) | ADORA1ALOX5ADORA3ADORA2ARAB9A | |
| SCHEMBL4823243 | 0.73 | CNR1 (0.49) | CNR1RAB9AALDH1A1MAPT | |
| SCHEMBL25556868 | 0.72 | ACP1 (0.47) | ADORA1ALOX5ADORA3ADORA2ARAB9A | |
| SCHEMBL9607736 | 0.72 | ADORA1 (0.51) | ADORA1ALOX5CNR1ADORA3ADORA2A | |
| SCHEMBL16490494 | 0.71 | NPC1 (0.59) | ADORA1ADORA3ADORA2ARAB9ANPC1 | |
| SCHEMBL22428619 | 0.71 | ADORA1 (0.46) | ADORA1ALOX5CNR1ADORA3ADORA2A | |
| SCHEMBL3116087 | 0.71 | GABBR2 (0.74) | ADORA1ADORA3ADORA2ARAB9ANPC1 | |
| SCHEMBL29363115 | 0.71 | ADORA1 (0.46) | ADORA1ALOX5CNR1ADORA3ADORA2A | |
| SCHEMBL3775348 | 0.70 | LRRK2 (0.69) | — | |
| SCHEMBL6076928 | 0.70 | PDE5A (0.46) | ADORA1ALOX5ADORA3ADORA2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | CNR1, CNR2, GPR18 | ADORA1 297/4885ALOX5 1452/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.